<DOC>
	<DOC>NCT01131845</DOC>
	<brief_summary>This is a single-center, open-label, single-dose evaluation of 1 mg UT-15C SR pharmacokinetics, safety, and tolerability in subjects with normal, mild, moderate and end stage renal disease (ESRD; on dialysis). Subjects in the ESRD group will receive 2 doses of UT-15C SR, separated by 14 days. One dose will be given 4 hours prior to dialysis, the other dose will be given at the end of dialysis. Pharmacokinetic samples will be taken immediately prior to dosing and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 24, 30, 36, 42 and 48 hours post dose. Additionally, subjects with ESRD will have a sample taken at 60 hrs post dose.</brief_summary>
	<brief_title>The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Male and female volunteers with ESRD (requiring dialysis), moderate (creatinine clearance; CrCL = 3050 mL/min), mild (CrCL = 5080 mL/min) and normal renal function (control group; (CrCL &gt;80 mL/min)) may be enrolled. Eligible subject will be 1879 years of age with a BMI between 18 40 kg/m2 and not taking chronic nonsteroidal antiinflammatory drugs (NSAIDs)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>